NVO, VKTX Stocks Fall as Lilly’s Zepbound, Mounjaro Sales Slow Down

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.

Share this Article:

This article was originally published here.